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Abstract
Smad7 is an inhibitory Smad and plays a protective role in obstructive and diabetic kidney disease. However, the role and
mechanisms of Smad7 in hypertensive nephropathy remains unexplored. Thus, the aim of this study was to investigate the
role and regulatory mechanisms of Smad7 in ANG II-induced hypertensive nephropathy. Smad7 gene knockout (KO) and
wild-type (WT) mice received a subcutaneous infusion of ANG II or control saline for 4 weeks via osmotic mini-pumps. ANG II
infusion produced equivalent hypertension in Smad7 KO and WT mice; however, Smad7 KO mice exhibited more severe
renal functional injury as shown by increased proteinuria and reduced renal function (both p,0.05) when compared with
Smad7 WT mice. Enhanced renal injury in Smad7 KO mice was associated with more progressive renal fibrosis with elevated
TGF-b/Smad3 signalling. Smad7 KO mice also showed more profound renal inflammation including increased macrophage
infiltration, enhanced IL-1b and TNF-a expression, and a marked activation of NF-kB signaling (all p,0.01). Further studies
revealed that enhanced ANG II-mediated renal inflammation and fibrosis in Smad7 KO mice were also associated with up-
regulation of Sp1 but downregulation of miR-29b expression. Taken together, the present study revealed that enhanced
Sp1-TGF-b1/Smad3-NF-kB signaling and loss of miR-29 may be mechanisms by which deletion of Smad7 promotes ANG II-
mediated renal fibrosis and inflammation. Thus, Smad7 may play a protective role in ANG II-induced hypertensive kidney
disease.
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Introduction
Hypertensive nephropathy, which is characterized by pro-
gressive renal fibrosis and inflammation, is a major complication of
hypertension and is one of the main causes of chronic kidney
disease [1]. It is widely accepted that angiotensin II (ANG II) is
a key mediator in hypertensive nephropathy and plays an essential
role in the progression of chronic kidney disease [2,3]. This is
supported by the finding that blockade of ANG II actions with
ACE inhibitors or angiotensin type 1 (AT1) receptor antagonists
can inhibit disease progression in human and experimental kidney
disease [4,5]. It is now clear that ANG II can activate several
intracellular signaling pathways to mediate renal fibrosis and
inflammation, including TGF-b/Smads, nuclear factor-kappa B
(NF-kB), and mitogen-activated protein kinases (MAPK) [6–10].
However, how these pathways are integrated in ANG II-mediated
hypertensive nephropathy remains largely unclear.
In the context of renal fibrosis, ANG II induces extracellular
matrix production through TGF-b-dependent and independent
mechanisms [9,10]. Within the TGF-b/Smad signaling cascade,
Smad3, but not Smad2, is a critical downstream mediator
responsible for renal and cardiovascular fibrosis [10–15]. Indeed,
many genes involved in tissue fibrosis (e.g. ColIa1, ColIa2,
ColIIIa1, ColVa2, ColVIa1, ColVIa3 and tissue inhibitor of
matrix metalloproteinase-1) are regulated by TGF-b/Smad3
signaling [16]. Thus, Smad3 plays an essential role in ANG II-
mediated fibrosis in vivo and in vitro [10–15].
Smad7 is an inhibitory Smad that negatively regulates TGF-b/
Smad-mediated renal fibrosis by facilitating degradation of TGF-
b receptor-1 and Smads via the Smurf2 and arkadia-dependent
ubiquitin-proteasome mechanism [17–20]. In chronic kidney
diseases, many mediators such as TGF-b1 and ANG II are able
to induce Smad7 mRNA expression, but Smad7 protein is
degraded [11,19–23]. As an adaptor protein for E3 ubiquitin
ligases such as Smurf2 and arkadia [17,20], Smad7 is degraded
once this ubiquitin cascade becomes activated. In renal fibrosis,
Smad7 protein levels are reduced. Evidence for protective role of
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Smad7 in renal fibrosis comes from studies in which Smad7 gene
knockout (KO) mice develop worse fibrosis in obstructed
nephropathy [23,24]. It has been reported that renal Smad7
levels are reduced in the rat remnant kidney and in cells in
response to ANG II [11,21]. However, the role of Smad7 in
hypertensive nephropathy in response to ANG II remains
unexplored. Therefore, in this study we determined the function
and underlying mechanisms of Smad7 in ANG II-mediated
hypertensive nephropathy through the use of Smad7 KO mice.
Materials and Methods
A Mouse Model of ANG II-induced Hypertension
Smad7 KO mice are generated in a CD-1 background mouse
strain from which functional Smad7 is disrupted by deleting exon I
in the Smad7 gene as previously described [25]. It is reported that
the CD-1 stain is more susceptible to renal injury in response to
ANG II [26]. Therefore, a mouse model of hypertensive
nephropathy was induced in littermate Smad7 KO or WT mice
(male mice, aged 8 weeks, 20–25 g) by subcutaneous infusion of
ANG II at a dose of 1000 ng/kg/min for 28 days via osmotic
minipumps as described previously [14,15]. Blood pressure was
measured weekly by the tail-cuff method using the CODA
noninvasive blood pressure system (Kent Scientific, Torrington,
CT) in conscious mice according to the manufacturer’s instruc-
tions. Kidney tissue samples were collected at day 28 for histology,
immunohistochemistry, Western blot, and real-time PCR analyses
as described previously [13–15]. Control mice received a saline
infusion instead of ANG II, following the same protocol. The
experimental procedures were approved by the Animal Experi-
mental Committee of The Chinese University of Hong Kong
(Permit No. 1165-05).
Proteinuria and Renal Function Analysis
Twenty-four hour urine samples were collected before and
weekly during ANG II infusion. Urine protein levels were
measured using the Quick start Bradford Dye Reagent (Bio-
RAD). Levels of both serum creatinine and urinary creatinine
were detected by the Enzymatic creatinine LiquiColor Reagent
(Stanbio Laboratory, Boerne, TX), according to the manufac-
turer’s instructions.
Histology and Immunohistochemistry
Renal morphology was examined in methyl Carnoy’s-fixed,
paraffin-embedded tissue sections (4 mm) stained with periodic
acid-Schiff (PAS) reagent. Immunohistochemistry was performed
in paraffin sections using a microwave-based antigen retrieval
method [22]. Primary antibodies used in the present study were:
collagen I (Southern Technology, Birmingham, AL), a-SMA
(Sigma, St. Louis, MO), TNFa, IL-1b, TGF-b1, phospho-Smad2/
3 (Santa Cruz Biotechnology, Santa Cruz, CA), phospho-NFkB/
p65 (Cell Signaling Technology, Danvers, MA), CD3 (Abcam,
Cambridge, MA), and F4/80 (Serotec, Oxford, UK). After being
incubated with the secondary antibody, sections were developed
with diaminobenzidine to produce a brown product and counter-
stained with hematoxylin. The percentage of positive area was
measured using a quantitative image-analysis system (Image-Pro
Plus 6.5, Media Cybernetics, Silver Spring, MD) as previously
described [13,14]. Briefly, the area of glomeruli and the
tubulointerstitium was outlined, and the positive signal measured
and expressed as the percentage of the area examined. For
quantitative analysis of F4/80+ macrophages, phospho-Smad3,
and phospho-p65+ cells, 20 consecutive glomeruli were counted
and data expressed as cells/glomerular cross-section (gcs), whereas
positive cells in the tubulointerstitium were counted under high-
power fields (640) by means of a 0.25-mm2 graticule fitted in the
eyepiece of the microscope and expressed as cells per millimeter
squared.
Western Blot Analysis
Protein from kidney tissues was extracted with RIPA lysis buffer
for Western blot analysis as previously described [13–15].
Nitrocellulose membranes were probed overnight with primary
antibodies against phospho-p65 (ser276), phospho-IkBa (ser32),
IkBa, phospho-Smad3 (s423–425) (Cell Signaling Technology),
Sp1 (H-225), p65, IkBa, Smad7 (Santa Cruz Biotechnology),
Smad3 (Zymed, San Francisco, CA), collagen I, a-SMA, or
GAPDH (Chemicon, Temecula, CA, USA), followed by in-
cubation with LI-COR IRDye 800-labeled secondary antibodies
(Rockland Immunochemicals, Gilbertsville, PA). The signal was
detected with Odyssey Infrared Imaging System (Li-COR
Biosciences, Lincoln, NE) and quantified using the Image J
program (National Institutes of Health). Protein levels are
expressed relative to the GAPDH control and presented as mean
6 SE.
Real-time PCR
Total kidney RNA was isolated using the RNeasy kit, according
to the manufacturer’s instructions (Qiagen, Valencia, CA) and
mRNA levels of collagen I, a-SMA, TGF-b1, IL-1b, and TNF-
a were measured by real-time PCR with primers as previously
described [13–15]. Sp1 was detected with primers: forward 59-
GCTGCCACCATGAGCGACCAA- 39, reverse 59-CACCGC-
CACCATTGCCGCTA- 39. For detection of miR-29b expres-
sion, renal RNA was isolated using TrizolH and expression of miR-
29b was examined with primers as previously described [27]. The
housekeeping gene GAPDH or U6 was used as an internal control.
Expression of the gene of interest relative to the internal control is
presented as mean 6 standard error (SE).
Statistical Analysis
Data are expressed as mean 6 SE. Statistical analysis was
performed using one-way analysis of variance (ANOVA), followed
by Newman-Keuls Post Test from the Prism Program (Prism 5.0
GraphPad Software, San Diego, CA).
Results
Deletion of Smad7 Enhances ANG II-mediated
Hypertensive Nephropathy
After Ang-II infusion, both WT and Smad7 KO mice
developed an equivalent increase in blood pressure over days 7
to 28 (Fig. 1A). However, Smad7 KO mice had higher levels of
proteinuria, serum creatinine, and a greater fall in the rate of
creatinine clearance (CCR) when compared to WT mice (Fig. 1,
B–D). PAS staining of kidney tissue showed that chronic ANG II
infusion caused more severe glomerular and vascular hypercellu-
larity and increased extracellular matrix accumulation within the
mesangium and tubulointerstitium in Smad7 KO mice when
compared to WT mice (Fig. 1E).
Deletion of Smad7 Promotes Renal Fibrosis and
Inflammation in ANG II-induced Hypertension
Immunohistochemistry revealed that compared with the saline-
treated mice, chronic ANG II infusion resulted in renal fibrosis in
WT mice, as demonstrated by a significant increase in collagen I
and a-SMA expression in both mRNA and protein levels, and the
Role of Smad7 in Hypertensive Nephropathy
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Figure 1. Deletion of Smad7 enhances ANG II-induced renal injury. A: Systolic blood pressure. B: Proteinuria. C: Serum creatinine. D:
Creatinine clearance (CCR). E: Histological damage [periodic acid-Schiff (PAS)-stained sections]. Note that disruption of Smad7 enhances ANG II-
mediated renal injury, including higher levels of proteinuria and serum creatinine, a greater fall in CCR, and histological damage such as glomerular
hypercellularity, vascular sclerosis (arrows), and ECM deposition when compared with Smad7 WT mice, despite equal levels of high blood pressure.
Values are means 6 SE for groups of 6 mice. Scale bar, 50 mM. *P,0.05, **P,0.01, ***P,0.001 compared with saline (SL) control mice. #P,0.05,
##P,0.01, ###P,0.001 compared with ANG II-infused Smad7 WT mice.
doi:10.1371/journal.pone.0053573.g001
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Figure 2. Deletion of Smad7 enhances ANG II-induced renal fibrosis. A: Collagen I. B: a-SMA. Immunohistochemistry (IHC, i, ii), real-time PCR
(iii), and Western blot (WB, iv, vi) analyses show that deletion of Smad7 enhances ANG II-induced renal fibrosis when compared with Smad7 WT mice.
Each bar represents means 6 SE for groups of 6 mice. Scale bar, 50 mM. *P,0.05, **P,0.01, ***P,0.001 compared with saline (SL) control mice.
#P,0.05, ##P,0.01, ###P,0.001 compared with ANG II-infused Smad7 WT mice.
doi:10.1371/journal.pone.0053573.g002
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accumulation of a-SMA+ myofibroblasts in the tubulointerstitium
(Fig. 2). These fibrotic responses were significantly enhanced in
Smad7 KO mice with chronic ANG II infusion as shown in
Figure 2.
ANG II infusion also induced inflammation in the kidney of
WT mice as shown by increasing mRNA and protein levels of the
pro-inflammatory cytokines TNF-a and IL-1b, as well as by
a significant macrophage infiltrate (Fig. 3). Again, ANG II-induced
these inflammatory responses were largely enhanced in Smad7
KO mice (Fig. 3).
Enhanced Activation of TGF-b1/Smad and NF-kB
Signaling Contributes to ANG-II Mediated Renal Fibrosis
and Inflammation in Smad7 KO Mice
To investigate the mechanisms by which deletion of Smad7
promoted Ang-II induced renal fibrosis and inflammation, we
studied TGF-b/Smad and NF-kB signaling pathways in the
hypertensive kidney. Immunohistochemistry, real-time PCR and
Western blot analysis revealed that ANG II infusion significantly
up-regulated renal TGF-b1 expression (Fig. 4A), resulting in high
levels of phospho-Smad2/3 and its nuclear translocation (Fig. 4B),
and a reduction of Smad7 protein levels in WT mice (Fig. 4C).
ANG II-induced upregulation of TGF-b1 and activation of Smad
signaling was further enhanced in Smad7 KO mice (Fig. 4).
Furthermore, both immunohistochemistry and Western blot
analyses revealed that although ANG II infusion caused significant
activation of the NF-kB signaling pathway, disruption of Smad7
resulted in enhanced activation of NF-kB/p65 in terms of
increased NF-kB/p65 phosphorylation and nuclear translocation
(Fig. 5A and B), which was associated with a reduction in the NF-
kB inhibitor, IkBa, on the basis of increased IkBa degradation by
phosphorylation while decreasing its mRNA expression (Fig. 5B
and C).
Deletion of Smad7 Upregulates Sp1 but Downregulates
miR-29b in ANG II-mediated Hypertensive Nephropathy
The transcriptional factor Sp1 has been shown to mediate ANG
II activities and can interact with both TGF-b/Smad and NF-kB
pathways [28–32]. We thus examined expression of Sp1 in ANG
II-mediated kidney disease. As shown in Figure 6 (A), renal Sp1
expression at the mRNA and protein level was up-regulated by
ANG II infusion in WT mice, which was further enhanced in the
hypertensive kidney of Smad7 KO mice.
We have recently shown that miR-29b is a downstream target of
TGF-b/Smad3 signalling and that down-regulation of miR-29b
promotes renal fibrosis [27]. As miR-29b is also negatively
regulated by the NF-kB-YY1-miR-29 regulatory circuit [33], we
hypothesized that a loss of renal miR-29b might contribute to the
enhanced renal fibrosis and inflammation seen in ANG II infused
Smad7 KO mice. As shown in Figure 6B, renal levels of miR-29b
were significantly reduced in ANG II infused WT mice and this
was further decreased in Smad7 KO mice in response to ANG II.
Discussion
Although it has been reported that deletion of Smad7 enhances
renal inflammation and fibrosis in obstructive nephropathy and
diabetic nephropathy [24,34], role of Smad7 in ANG II-mediated
hypertensive nephropathy, a major cause of end-stage kidney
disease, remains unexplored. The present study identified that
Smad7 plays a protective role in ANG II-mediated hypertensive
nephropathy. The findings that disruption of Smad7 enhanced
ANG II-induced renal injury by promoting TGF-b/Smad2/3-
mediated renal fibrosis and NF-kB-driven renal inflammation
added new information for a better understanding of the
mechanism of Smad7 in negatively regulating ANG II-mediated
kidney injury. Furthermore, the findings that enhanced TGF-b/
Smad3-mediated renal fibrosis and NF-kB-dependent renal in-
flammation in Smad7 KO mice were associated with up-
regulation of Sp1 and down-regulation of miR-29b in the
hypertensive kidney also provided new mechanisms for un-
derstanding the protective role of Smad7 in ANG II-mediated
hypertensive nephropathy. Thus, we identified that ANG II-
mediated hypertensive kidney injury involves the complex and
integrated mechanisms. Of these, Smad7 is an important regulator
which operates via direct and indirect mechanism to suppress
ANG II-mediated renal fibrosis and inflammation.
An important finding in the present study is that loss of Smad7
promoted ANG II-induced activation of TGF-b/Smad signaling,
resulting in a progressive renal fibrosis in a mouse model of
hypertension. This finding largely extended a previous observation
in vitro that ANG II-induced TGF-b/Smad3-mediated renal
fibrosis in cultured renal tubular epithelial cells is associated with
down-regulation of Smad7 via AT1R-Smurf2-dependent ubiqui-
tin degradation of Smad7 [11]. It has been shown that after
binding to the AT1 receptor, ANG II induces fibrosis by directly
activating TGF-b/Smad signaling and by indirectly activating
TGF-b/Smad signaling via a ERK/p38 MAP kinase-Smad cross-
talk mechanism [9,10]. We recently demonstrated that Smad3, but
not Smad2, is the key transcription factor responsible for TGF-b-
mediated renal fibrosis [10–13]. Thus, deletion of Smad3 is
capable of preventing ANG II-mediated cardiac remodeling and
renal fibrosis [14,15]. The present finding that disrupted Smad7
enhanced Smad3-mediated renal fibrosis added a new evidence
for a protective role of Smad7 in ANG II-mediated hypertensive
nephropathy.
Enhanced NF-kB-driven renal inflammation may be the key
mechanism through which disruption of Smad7 promoted ANG
II-induced renal inflammation as demonstrated by up-regulation
of pro-inflammatory cytokines (IL-1b and TNF-a) and infiltration
of F4/80+ macrophages. This is consistent with the previous
findings in non-hypertensive kidney disease in which disruption of
Smad7 promots NF-kB-dependent renal inflammation in obstruc-
tive and diabetic nephropathy [24,34], arguing that Smad7 is of
general importance in the regulation of renal inflammation under
various pathological conditions. It has been reported that over-
expression of Smad7 is capable of inhibiting NF-kB-driven renal
inflammation by up-regulating the NF-kB inhibitor, IkBa [34–
37]. By using Smad7 KO mice, the present study provided new
evidence that inhibition of IkBa mRNA expression and promoted
its degradation by phosphorylation may be an essential mecha-
nism by which deletion of Smad7 enhanced ANG II-induced
activation of NF-kB/p65 and renal inflammation.
Interestingly, we also found that deletion of Smad7 promoted
ANG II-induced upregulation of Sp1 in the hypertensive kidney.
This new finding suggests that enhanced ANG II-induced Sp1
pathway may be an additional mechanism by which mice lacking
Smad7 were promoted ANG II-mediated renal inflammation and
fibrosis. Indeed, Sp1 is required for ANG II–induced fibrotic and
inflammatory response [28,29]. It is also reported that Sp1 can
interact with Smad3 to enhance TGF-b-induced fibrotic response
[29–31]. Thus, ANG II-induced up-regulation of Sp1 expression
and activation of Smad3 may cooperate in the development of
ANG II-induced renal fibrosis as seen in WT mice. Whereas,
deletion of Smad7 may result in a further increase in Sp1-Smad3
interaction, thereby enhancing ANG II-mediated renal fibrosis. In
addition, Sp1 is capable of interacting with NF-kB to play a critical
role in autoimmune disease and cancer [32,38]. Thus, enhanced
Role of Smad7 in Hypertensive Nephropathy
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Figure 3. Deletion of Smad7 enhances ANG II-induced renal inflammation. A: TNFa. B: IL-1b. C: F4/80+ macrophages.
Immunohistochemistry (IHC, i, ii) and real-time PCR (iii) analyses show that deletion of Smad7 enhances ANG II-induced renal inflammation with
up-regulation of TNFa and IL-1b, and an increased macrophage infiltrate when compared with Smad7 WT mice. Each bar represents means 6 SE for
groups of 6 mice. Scale bar, 50 mM. *P,0.05, **P,0.01, ***P,0.001 compared with saline (SL) control mice. #P,0.05, ##P,0.01 when compared
with ANG II-infused Smad7 WT mice.
doi:10.1371/journal.pone.0053573.g003
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Figure 4. Deletion of Smad7 enhances ANG II-induced activation of TGF-b1/Smad3 signaling in the kidney. A: TGF-b1 expression
detected by immunohistochemistry (i ii) and real-time PCR (iii). B: Activation of Smad3 determined by immunohistochemistry for phospho-Smad2/3
nuclear translocation (i, ii) and Western blots for phosphorylation levels of Smad3 in the kidney (iii, iv). C: Smad7 protein levels. Note that ANG II
induces degradation of renal Smad7 protein in the Smad7 WT. Each bar represents means 6 SE for groups of 6 mice. Scale bar, 50 mM. *P,0.05,
**P,0.01, ***P,0.001 compared with saline (SL) control mice. #P,0.05, ##P,0.01, ### P,0.001 when compared with ANG II-infused Smad7 WT
mice.
doi:10.1371/journal.pone.0053573.g004
Role of Smad7 in Hypertensive Nephropathy
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Figure 5. Deletion of Smad7 enhances ANG II-induced activation of NF-kB/p65 in the kidney. A: Immunohistochemistry detects that
deletion of Smad7 enhances phospho-NF-kB/p65 nuclear translocation in the hypertensive kidney. B: Western blot analysis shows that disruption of
Smad7 promotes IkBa degradation through phosphorylation, thereby enhancing NF-kB activation as determined by significantly increasing
phosphorylation of p65 in the hypertensive kidney. C. Real-time PCR shows that deletion of Smad7 significantly inhibits IkBa mRNA expression in
mice after ANG II infusion. Each bar represents means 6 SE for groups of 6 mice. Scale bar, 50 mM. *P,0.05, ***P,0.001 compared with saline (SL)
control mice. #P,0.05, ##P,0.01 when compared with ANG II-infused Smad7 WT mice.
doi:10.1371/journal.pone.0053573.g005
Role of Smad7 in Hypertensive Nephropathy
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both ANG II-induced up-regulation of Sp1 expression and
activation of NF-kB signaling may account for exacerbation of
ANG II-induced renal inflammation in Smad7 KO mice.
Furthermore, loss of miR-29 may also be a mechanism through
which disruption of Smad7 enhances Ang II-mediated renal
fibrosis and inflammation. miR-29 exerts an anti-fibrotic function
through direct targeting of the 3’UTR regions in the mRNA for
collagens I, III and IV and fibrillin and elastin [39]. We have
previously demonstrated that Smad3 can physically interact with
the miR-29b promoter to negatively regulate miR-29b expression
in response to TGF-b1 in vitro and in obstructive nephropathy
[27]. miR-29 is also negatively regulated by the NF-kB-YY1-miR-
29 regulatory circuit in cancer cells [33]. Thus, down-regulation of
miR-29 in ANG II-mediated hypertensive nephropathy may be
attributed to activation of both TGF-b/Smad3 and NF-kB
pathways. Moreover, miR-29 can inhibit TGF-b1 and Sp1
expression [40,41]. Taken together, ANG II-induced loss of
miR-29b via the TGF-b/Smad3 and NF-kB-dependent mecha-
nism may result in further increase in TGF-b1 and Sp1-dependent
renal injury. Therefore, loss of miR-29 may also be a new
mechanism by which deletion of Smad7 enhanced ANG II-
mediated renal injury via the Sp1-TGF-b/Smad3-NF-kB-miR29
auto-regulatory loop.
It should be pointed out that although Smad7 exerts its
protective role in both renal fibrosis and inflammation, role of
TGF-b1 under disease conditions is highly diverse due to the
complexity of its downstream signaling pathway [42]. In the
context of fibrosis and inflammation, Smad3 is pathogenic, while
Smad2 and Smad7 are protective. Smad4 exerts its diverse roles
by transcriptionally enhancing Smad3-mediated renal fibrosis
while inhibiting NF-kB-driven renal inflammation [42]. In
addition, unlike active TGF-b1 which mediates progressive renal
fibrosis [43], mice overexpressing latent TGF-b1 are protected
against progressive renal inflammation and fibrosis in obstructive
and immunologically-induced crescentic glomerulonephritis via
the Smad7-dependent mechanism [35,44,45]. All these studies
suggest that specific targeting the downstream TGF-b/Smad3
signaling pathway by overexpression of Smad7, rather than
blocking the general effect of TGF-b1 with neutralizing antibodies,
may represent a specific and effective therapeutic strategy for
kidney disease [46].
In summary, the current study found that disruption of Smad7
significantly increases Ang-II induced renal fibrosis and inflam-
mation. Enhanced Sp1-TGF-b1/Smad3-NF-kB signaling may be
the major mechanistic pathway by which deletion of Smad7
promotes ANG II-mediated renal fibrosis and inflammation.
Thus, Smad7 plays a protective role in ANG II-induced
hypertensive nephropathy. Results from this study suggest that
strategies that can increase Smad7 levels may have therapeutic
potential for hypertensive nephropathy.
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